申请人:Shionogi&Co., Ltd.
公开号:EP2184272A1
公开(公告)日:2010-05-12
A compound which specifically binds to a receptor of NR1/ NR2B, and is used as a NR2B receptor antagonist is provided.
It has been found out that a piperazine derivative represented by the formula (I) binds specifically to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist.
A compound represented by:
wherein R1 is each independently C1-C3 alkyl or the like, m is an integer of 0 to 4, X is -N(R4)-C(=O)-C(=O)-, -N(R4)-(CR5R6)p-C(=O)-, -N(R4)-C(-O)-(CR7R8)q- or -C(=O)-N(R4)-(CR7R8)q-, p and q are each independently an integer of 1 to 3, R4, R5, R6, R7 and R8 are each independently a hydrogen atom or lower alkyl, A1 is benzoxazolinone or the like, and A2 is optionally substituted phenyl or the like, or a pharmaceutically acceptable salt or a solvate thereof.
提供了一种能与 NR1/ NR2B 受体特异性结合并用作 NR2B 受体拮抗剂的化合物。
研究发现,由式(I)代表的哌嗪衍生物能与 NR1/NR2B 受体特异性结合,并可用作 NR2B 受体拮抗剂。
由以下式子代表的化合物
其中 R1 各自独立地为 C1-C3 烷基或类似物,m 为 0 至 4 的整数,X 为-N(R4)-C(=O)-C(=O)-、-N(R4)-(CR5R6)p-C(=O)-、-N(R4)-C(-O)-(CR7R8)q-或-C(=O)-N(R4)-(CR7R8)q-,p 和 q 各自独立地为 1 至 3 的整数、R4、R5、R6、R7 和 R8 各自独立地为氢原子或低级烷基,A1 为苯并恶唑啉酮或类似物,A2 为任选取代的苯基或类似物,或其药学上可接受的盐或溶液。